Drugs / REGN20423
last change May 2026 re-read 3 minutes ago

REGN20423

Developed for
atopic eczema
Investigated by
Regeneron Pharmaceuticals

Trials 1

20272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07527923 May 2026 → Jun 2028 expected atopic eczema Regeneron Pharmaceuticals Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as REGN20423 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07527923 ↗